Jay N Cohn MD, FAHAProfessor of Medicine in the Cardiovascular Division, Director, Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota Medical School, Minneapolis, MN
Dr. Cohn is internationally recognized for his seminal contributions to our understanding of the pathophysiology of cardiovascular disease and for his innovative research into modernization of the treatment of hypertension, shock, acute myocardial infarction and heart failure. His recent efforts have focused on a new approach to recognize the functional and structural markers of early cardiovascular disease in order to introduce effective therapy aimed at slowing its progression to morbid events.
He has received awards for his pioneering research from the American Heart Association, the American College of Cardiology, the High Blood Pressure Research Council, the American Society of Hypertension, the Heart Failure Society of America, the International Academy of Cardiovascular Sciences, the Arrigo Recordati International Foundation, Cornell University Medical School and the University of Minnesota Academic Health Center. He founded and served as first president of the Heart Failure Society of America and has served as president of the American Society of Hypertension, the International Society of Hypertension, and the International Society of Cardiovascular Pharmacotherapy.
He is the author of over 700 peer-reviewed publications in the medical literature, is the co-editor of the major medical textbook, Cardiovascular Medicine, and holds numerous patents on his research discoveries
Recent Contributions to PracticeUpdate:
- Safety of Alpha Adrenergic Receptor Antagonists in Heart Failure
- Afterload Hypersensitivity in Patients With Left Bundle Branch Block
- Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block
- Efficacy of Intravenous Furosemide vs a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure
- MY APPROACH to the Patient With Heart Failure and Improved Ejection Fraction
- Evidence and Considerations for the Role of Biomarkers in Heart Failure
- Assessing the Risk of Progression From Asymptomatic LV Dysfunction to Overt Heart Failure
- Comparative Effectiveness of ACE Inhibitor–Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks vs Whites